Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Condition(s) studied

Investigational drug(s) / intervention(s)

GLP-1 receptor agonist: Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.

responders group and nonresponders group: For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks. Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months. According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated.

Study summary

This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.

Eligibility

Primary outcome measure(s)

• Change from baseline HbA1c and baseline weight at 6 month — 6 month after GLP-1 RA treatment
  In order to observe the change from baseline HbA1c and baseline weight at 6 month after GLP-1 RA treatment
• To identify and evaluate the variable factors influencing GLP-1 RA efficacy — 1 month after sample integration
  The variable factors that predict the efficacy of GLP-1 RA were identified and the weight these variables on the efficacy was assessed
• Genotype identification in patients with T2DM — 1 month after sample collecting
  Blood samples were collected from T2DM patients for genotyping

Trial sites (1)

More The Affiliated Hospital of Xuzhou Medical University trials in China

Other trials for the same condition